When Clinigen (CLIN) acquired cancer supportive care product Cardioxane from Novartis in 2013, one of its key targets for widening its use was to remove the restrictions for use in children. Although reaching that target has taken longer than planned, the European Medicines Association has now lifted that restriction, which should increase the potential for the drug. As a result, broker Numis expects 5 per cent compound annual growth in Cardioxane between 2016 and 2021 to £5.2m.
IC TIP:
Hold
at
855p
